Henan Newland Pharmaceutical Co. Ltd. A (301277) — Working Capital to Net Assets Ratio
Henan Newland Pharmaceutical Co. Ltd. A (301277) has a Working Capital to Net Assets ratio of 58.7% as of March 2026. Working capital of CN¥931.71 Million (current assets of CN¥1.11 Billion minus current liabilities of CN¥174.11 Million) is measured against net assets of CN¥1.59 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Henan Newland Pharmaceutical Co. Ltd. A (301277) flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Henan Newland Pharmaceutical Co. Ltd. A Working Capital to Net Assets (2020–2025)
This chart shows how Henan Newland Pharmaceutical Co. Ltd. A's Working Capital to Net Assets ratio has evolved across 6 annual periods from 2020 to 2025. As of March 2026, the ratio stands at 58.7%, reflecting working capital of CN¥931.71 Million against net assets of CN¥1.59 Billion CNY. See how many days can Henan Newland Pharmaceutical Co. Ltd. A fund operations to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Henan Newland Pharmaceutical Co. Ltd. A (2020–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2025, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Henan Newland Pharmaceutical Co. Ltd. A (301277) total market value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 57.8% | CN¥896.33 Million | CN¥1.55 Billion | CN¥1.07 Billion | CN¥170.35 Million | ▼ -5.6 pp |
| 2024 | 63.4% | CN¥978.24 Million | CN¥1.54 Billion | CN¥1.20 Billion | CN¥216.78 Million | ▼ -6.8 pp |
| 2023 | 70.2% | CN¥1.02 Billion | CN¥1.45 Billion | CN¥1.16 Billion | CN¥139.47 Million | ▼ -5.7 pp |
| 2022 | 75.9% | CN¥1.03 Billion | CN¥1.36 Billion | CN¥1.19 Billion | CN¥156.01 Million | ▲ +31.5 pp |
| 2021 | 44.4% | CN¥180.43 Million | CN¥406.38 Million | CN¥401.00 Million | CN¥220.58 Million | ▲ +15.4 pp |
| 2020 | 29.0% | CN¥90.76 Million | CN¥313.39 Million | CN¥268.49 Million | CN¥177.73 Million | — |